Regina I. Jakacki

Pediatrics

3705 5th Ave Rm 4B385
Pittsburgh, PA 15213

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Magnetic Resonance Spectroscopy Metabolites as Biomarkers of Disease Status in Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) Treated with Glioma-Associated Antigen Peptide Vaccines.

Magnetic Resonance Spectroscopy Metabolites as Biomarkers of Disease Status in Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) Treated with Glioma-Associated Antigen Peptide Vaccines.

Journal: Cancers

Published: September 06, 2022

Quantitative Sodium (23Na) MRI in Pediatric Gliomas: Initial Experience.

Quantitative Sodium (23Na) MRI in Pediatric Gliomas: Initial Experience.

Journal: Diagnostics (Basel, Switzerland)

Published: March 17, 2022

Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report.

Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report.

Journal: Neuro-oncology

Published: May 13, 2020

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

Journal: The Lancet. Oncology

Published: February 06, 2019

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.

Journal: Neuro-oncology

Published: March 25, 2017

Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience.

Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience.

Journal: Neuroimaging clinics of North America

Published: November 28, 2016

Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas.

Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas.

Journal: Neuro-oncology

Published: August 12, 2016

Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.

Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.

Journal: Journal of neuro-oncology

Published: May 10, 2016

Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.

Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.

Journal: Neuro-oncology

Published: December 06, 2015

Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.

Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.

Journal: Neuro-oncology

Published: October 31, 2015

Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study.

Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study.

Journal: Journal of neuro-oncology

Published: September 14, 2015

Amplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis.

Amplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis.

Journal: Melanoma research

Published: August 13, 2015

Showing 1-12 of 42

Last Updated: 09/26/2026